United States v. Berman

District Court, District of Columbia·Decided May 16, 2025·No. Criminal No. 2020-0278·Published

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

UNITED STATES,

v.

No. 20-cr-00278 (TNM)

KEITH BERMAN,

Defendant.

MEMORANDUM ORDER*

The Court must determine the amount of restitution that Defendant Keith Berman owes the victims of his fraud. Berman challenges the Government’s proffered sum on two grounds. First, he insists that one of the tendered award recipients is not a “victim” under the Mandatory Victims Restitution Act. On that front, the Court agrees. This would-be recipient was not directly harmed by the conduct underlying Berman’s offense of conviction. Second, Berman argues that the Government failed to prove that various stock losses happened during the fraud period. There, the Court disagrees. The Victim Impact Statements establish that the challenged stock purchases were made relying on Berman’s misrepresentations, indicating they were purchased during the fraud period. Finally, the Court determines that Berman’s precarious financial condition renders him unable to pay the full amount of the restitution order immediately. It thus instructs Berman to pay a reduced monthly sum.

I.

In late 2023, Keith Berman pled guilty to three felonies: securities fraud, wire fraud, and obstruction of Securities and Exchange Commission (“SEC”) proceedings. Superseding Indictment, ECF No. 19, at 20–22; Def.’s Stmt. Supp. Guilty Plea, ECF No. 170 (“Def.’s

*

An unredacted version of this Order was filed under seal on April 30, 2025.

Stmt.”). The charges stemmed from Berman’s fraudulent conduct as CEO of his publicly traded company, Decision Diagnostics Corp. Superseding Indictment ¶ 3; Def.’s Stmt. at 3. In early 2020, Decision Diagnostics and its CEO were facing financial straits. Superseding Indictment ¶ 9; Def.’s Stmt. at 3. The company’s blood-glucose monitoring and testing devices were not bringing in the profits that Berman needed. Superseding Indictment ¶ 9. But the onset of the COVID-19 pandemic brought about new business opportunities—and potential salvation. Superseding Indictment ¶ 15; Def.’s Stmt. at 3. Berman believed he could restructure existing technology to develop a groundbreaking device able to detect the rampant virus in the bloodstream, known as “impedance” technology. Superseding Indictment ¶ 11 (“BERMAN wrote an email in which he stated, ‘We have a lot at stake here . . . . [T]his coronavirus through impedance is the story that will allow me to raise millions.”); Def.’s Stmt. at 3. He just needed a little help—and he was willing to break a few rules to get it.

In the first frightening months of the pandemic, Berman issued a series of press releases that greatly exaggerated the company’s progress developing the detection device. Superseding Indictment ¶¶ 18–35; Def.’s Stmt. at 3. Though Berman’s technical advisors expressed serious doubts as to the viability of using impedance technology to test for COVID-19, Berman did not reveal this to the public. Superseding Indictment ¶¶ 17–19. Instead, he lauded Decision Diagnostics’ “break-through” new technology, which he claimed the company had already “perfected.” Id. ¶ 18. He announced that the technology “provided a positive or negative result in 15 seconds based on a small finger prick blood sample,” and that since “government fast track and waivers” had already begun, the test kits would be “commercial ready in summer 2020.” Id.

None of this was true. Decision Diagnostics had developed no test kit at all, much less one that could accurately detect the virus in 15 seconds. Id. ¶ 19. Nor did Berman have any

evidence that the impedance method could actually work. Id. And the company had taken no steps towards obtaining any government approvals for a product that remained entirely speculative. Id.

Berman was undeterred. He continued to issue press releases representing that Decision Diagnostics was “making significant progress toward bringing the product to market and would be ready to manufacture and sell hundreds of millions of units in the first year.” Id. ¶ 20. Behind the scenes, Berman’s vendor was repeatedly informing him that the proposed impedance method was unlikely to be scientifically viable. Id. The vendor ultimately concluded and communicated to Berman that the impedance method would never work. Id. ¶ 22. Still, Berman did not disclose that devastating development to the market. Id. Instead, he continued to assure investors that Food & Drug Administration (“FDA”) emergency approval was forthcoming. Id. ¶¶ 23–25, 28–31, 34 (“On or about April 23, 2020, BERMAN authorized a press release stating that DECN had ‘completed discussions and have come to an understanding with the FDA on all of the testing required . . . . We plan to engage a specialty reference laboratory to complete this testing in the next 10 days. Testing should take about a week.”). In reality, the FDA approval was stalled because the agency required clinical testing. Id. ¶ 31. But Decision Diagnostics could not submit to testing because it lacked a prototype and the necessary insurance to conduct reliable testing on human subjects. Id. ¶ 26.

In the meantime, the SEC had begun to investigate Decision Diagnostics and Berman.

Id. ¶ 36; Def.’s Stmt. at 3. In April 2020, the SEC suspended trading in the company’s stock due to its concerns that Berman was materially misrepresenting the progress of its impedance technology to investors. Superseding Indictment ¶ 49; Def.’s Stmt. at 3. Berman was displeased. Pretending to be an independent shareholder of Decision Diagnostics, Berman

reached out to a contact (referred to as “Person 2” in the indictment) and directed the contact to draft a letter to the SEC regarding the stock suspension. Superseding Indictment ¶ 53; Def.’s Stmt. 3–4. The letter accused the SEC of unethical and inappropriate conduct against Decision Diagnostics. Superseding Indictment ¶ 58; Def.’s Stmt. 4. Berman directed his contact to gather signatures from the other shareholders before sending the letter to the agency. Superseding Indictment ¶ 57; Def.’s Stmt. 4. Berman himself signed the shareholder letter using the alias “Matthew Steinmann.” Superseding Indictment ¶ 58. But Berman would later tell law enforcement agents that neither he nor his company had anything to do with the letter to the SEC. Id. ¶ 64. Berman “engaged in this conduct to influence the SEC to end its investigation into [Decision Diagnostics] and [himself.]” Def.’s Stmt. at 4.

All told, Berman’s misrepresentations caused his investors to lose at least hundreds of thousands of dollars. Superseding Indictment ¶ 65; Restitution Notice, ECF No. 190, at 1 (Government calculating losses to shareholders over $1 million). Between early March 2020 and the trading suspension, the company’s stock price had risen by over 1500%. Superseding Indictment ¶ 37. After the fraud came to light, the stock became worthless. Id. ¶ 65.

In light of Berman’s guilty plea, the Court sentenced him to 84 months of incarceration on the securities fraud and wire fraud counts, as well as 60 months on the obstruction charge, all to run concurrently. Judgment, ECF No. 197, at 3. The incarceration terms were to be followed by a term of 36 months of supervised release. Id. at 4. Before sentencing, the Government noted its intent to seek restitution and calculated the amount it saw as due. Restitution Notice at 2.

The Government provided Victim Impact Statements from individual victims to corroborate the total sum it was seeking from Berman. See ECF Nos. 206-1–206-26.

The Court reserved the determination of the amount resolution of restitution for a later date. Minute Entry April 12, 2024; see also Dolan v. United States, 560 U.S. 605, 608 (2010) (holding that a sentencing court may order restitution more than 90 days after sentencing when the court “made clear prior to the deadline’s expiration that it would order restitution, leaving open (for more than 90 days) only the amount.”). The Court now determines the amount of restitution Berman owes his victims.

II.

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Berman, (D.D.C. 2025).

United States v. Berman (United States v. Berman) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Pepper
51 F.3d 469 (Fifth Circuit, 1995)
United States v. Marino
654 F.3d 310 (Second Circuit, 2011)
United States v. Eddie Lee Alston A/K/A Eddie Lee
609 F.2d 531 (D.C. Circuit, 1979)
United States v. Gary Bennett
943 F.2d 738 (Seventh Circuit, 1992)
United States v. Edward J. Brothers
955 F.2d 493 (Seventh Circuit, 1992)
United States v. George W. Jewett, Jr.
978 F.2d 248 (Sixth Circuit, 1992)
United States v. John M. Turino
978 F.2d 315 (Seventh Circuit, 1992)
United States v. Loren M. Welsand
23 F.3d 205 (Eighth Circuit, 1994)
United States v. Henoud
81 F.3d 484 (Fourth Circuit, 1996)
United States v. Taiwo Adeshola Akande
200 F.3d 136 (Third Circuit, 1999)
United States v. Luiz Ben Zvi
242 F.3d 89 (Second Circuit, 2001)
In Re Sealed Case
702 F.3d 59 (D.C. Circuit, 2012)
In Re Interbank Funding Corp. Securities Litigation
668 F. Supp. 2d 44 (District of Columbia, 2009)
United States v. John Farano
749 F.3d 658 (Seventh Circuit, 2014)
United States v. Mitchell J. Stein
846 F.3d 1135 (Eleventh Circuit, 2017)